Spectral AI, Inc.
Spectral AI, Inc. is a Dallas-based healthcare AI company developing predictive diagnostic technology for wound care. Its main product, the DeepView System, combines imaging and AI to assess burn wounds and help clinicians make faster treatment decisions; the company has also described applications in diabetic foot ulcers. Spectral AI is publicly traded on Nasdaq under the ticker MDAI. Its market position is that of a specialist medical-device and diagnostics developer focused on AI-enabled wound assessment, with a major U.S. government development relationship through BARDA. The company’s 2025 annual report announcement said it had submitted a De Novo application for DeepView’s burn indication; the available research results do not establish the subsequent regulatory outcome.
Company Details
- Website
- spectral-ai.com
- Headquarters
- Dallas, Texas, United States
- Founded
- 2009
- Funding
- Undisclosed; publicly available results cite $54.9 million in BARDA funding committed to date under
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring